AI-Assisted Colonoscopies and the Quiet Reshaping of Diagnostic Medicine

Lead

The numbers, on their face, are the kind that attract headlines. During the three months before an artificial-intelligence tool was introduced into a colonoscopy workflow, clinicians at the reporting centre found at least one adenoma — the precancerous polyp that screening exists to catch — in 28.4 per cent of procedures. In the three months after, the adenoma detection rate rose to a markedly higher figure. The pre/post comparison, summarised on 26 June 2026 by Indian outlet thePrint, has circulated widely because the absolute jump is large enough to be commercially meaningful and because the metric in question — adenoma detection rate, or ADR — is the standard by which endoscopists are judged and, increasingly, paid.

The detail that has attracted less attention is what the study does and does not establish. It is a single-centre, before-and-after comparison. It does not randomise patients, it does not blind endoscopists to which cases the algorithm flagged, and it does not yet report interval-cancer outcomes. It does, however, capture something real: when a real-time computer-aided detection system sits in the room, the polyps that get removed are not the same ones that would have been removed without it.

Nut graf

That single result sits at the centre of a much larger argument about how diagnostic medicine absorbs machine intelligence — slowly in some places, abruptly in others, and almost always without the regulatory architecture that would let a clinician, a hospital administrator or a patient know exactly what the tool is doing. The Indian data point is a useful one precisely because it is small, concrete and verifiable: a known baseline rate, a known intervention, a known post-intervention rate, all reported from a single tertiary centre. The temptation, in a sector prone to hype, is to treat such numbers as proof of a revolution. The more defensible reading is that they confirm what every other recent evaluation has shown — that computer-aided detection in endoscopy shifts what clinicians see — while leaving the harder questions, about cost, governance and clinical benefit, unanswered.

What the Indian data actually shows

The figures reported by thePrint on 26 June 2026 are simple and worth repeating in full. In the three months before the AI tool was introduced, the adenoma detection rate at the centre was 28.4 per cent. In the three months after introduction, the rate rose into the mid-forties — a near-doubling of the baseline that, in absolute terms, translates into thousands of additional polyps identified per year at a busy screening unit.

ADR is not a vanity metric. It is one of the few quality indicators in gastroenterology with a documented link to downstream outcomes: higher detection rates correlate with lower rates of post-colonoscopy colorectal cancer, the cancers that appear between screening rounds in patients whose initial procedure was reported as clean. For that reason, professional societies on both sides of the Atlantic have spent the better part of a decade pushing baseline ADR upward, and for that reason a tool that lifts ADR by more than ten percentage points in a single site will attract the attention of hospital procurement officers before it attracts the attention of regulators.

The published summary does not name the centre, the vendor, or the specific algorithm deployed, which limits the ability of outside researchers to assess selection effects. But the directionality of the result is consistent with the broader literature: a series of randomised trials in Europe, the United States and East Asia have repeatedly shown that real-time AI assistance raises polyp detection, with the largest gains typically accruing to the least-experienced endoscopists in the cohort. The Indian finding, in other words, is not anomalous. It is one more data point on a curve that has been bending in the same direction for several years.

The counter-narrative: detection is not survival

The instinctive critique — and the one that has surfaced in clinical commentary on earlier AI-endoscopy trials — is that detection is a proxy, not an outcome. A study can lift ADR by double digits and still leave post-colonoscopy cancer rates, mortality and cost-of-care unchanged, because the additional polyps removed are disproportionately small, low-grade lesions that would never have progressed to invasive disease. The argument is structurally similar to the one that ran through prostate cancer screening two decades ago: more diagnoses do not automatically mean fewer deaths, and in some cases mean more treatment of disease that did not need treating.

There is also a subtler objection. Adenoma detection is a behaviourally responsive metric. Endoscopists who know their ADR is being measured already withdraw the scope more slowly, examine folds more carefully and adjust their technique in ways that lift detection independent of any new tool. When an AI system is layered on top of that pre-existing improvement loop, the marginal contribution of the algorithm becomes harder to isolate — particularly in a single-arm, before-and-after design, where maturation effects and secular trends in detection practice cannot be disentangled from the effect of the software.

A serious reading of the Indian data therefore treats it as a plausibility signal rather than a verdict. The study is consistent with the algorithm contributing meaningfully to detection. It is not, on its own, evidence that the algorithm changes what matters most: whether fewer patients die of interval colorectal cancer in the years that follow.

What the regulatory and procurement environment looks like

The Indian study lands in a regulatory environment that has so far declined to treat computer-aided detection in endoscopy as a high-risk device requiring pre-market clinical-trial evidence comparable to a new drug. In the United States, the Food and Drug Administration has cleared a handful of GI-cadence AI tools through its 510(k) pathway, which relies on substantial equivalence to a predicate device rather than on de novo clinical-outcome data. In Europe, CE marking under the Medical Device Regulation has moved more slowly than US clearance for some products, in part because notified bodies have become more cautious about software-as-a-medical-device claims since 2023. India’s Central Drugs Standard Control Organisation has, to date, approved computer-aided endoscopy systems through a process that does not routinely require published prospective trials before market entry.

The practical consequence is that a hospital can buy an AI endoscopy system, deploy it across an entire service, and bill for procedures whose clinical value has been demonstrated only by intermediate metrics such as ADR. The Indian dataset is, in effect, the kind of evidence the system already has — and is, by the same token, the kind of evidence that downstream payers and regulators will eventually demand be backed up with longer-horizon outcomes. The current arrangement works as long as the proxies hold. It becomes harder to defend the day an algorithm is shown to lift ADR while leaving mortality unchanged, or to lift ADR while introducing a measurable false-positive cost in unnecessary polypectomies and pathology.

The structural frame: software inside the scope

The colonoscopy suite has been an unusually honest site for the introduction of clinical AI because the metric being targeted is measurable, routinely reported and clinically meaningful. That has made it easier to evaluate than most of the other places machine learning is now being inserted — radiology triage, sepsis prediction, ambient clinical notetaking, patient-flow forecasting — where the relevant outcome is harder to define and harder still to measure. Endoscopy is also unusual because the AI sits inside the procedural workflow in real time, not in a back office. The clinician sees what the algorithm sees, and the algorithm’s confidence score is rendered onto the same monitor as the image. That intimacy changes the social dynamics of adoption in ways that earlier clinical-software generations did not have to navigate.

What is happening in endoscopy is therefore best read as a leading indicator of how diagnostic medicine more broadly will absorb machine intelligence. The pattern repeats: a vendor arrives with a study showing improvement on a proxy metric; a hospital buys the tool; a payer eventually asks whether the proxy is the right one; and the answer is usually deferred until enough real-world data has accumulated to either validate or embarrass the original claim. The Indian data point sits at the very beginning of that cycle.

What remains uncertain

The published summary does not specify several things a careful reader would want to know. It does not name the centre or the algorithm vendor; it does not report endoscopist-level variation, which would help separate individual improvement from system-wide effect; it does not report histology of the additional lesions, which would clarify whether the algorithm is mostly surfacing high-risk polyps or low-risk ones; and it does not report false-positive rates, which determine the downstream cost of polypectomy and pathology. The pre/post design, by construction, cannot account for maturation effects in the endoscopist cohort. None of these gaps is fatal — each is the kind of question a follow-up study would answer — but they are the questions on which the eventual verdict will turn.

The wider literature on AI in endoscopy, including the European and East Asian randomised trials that have preceded the Indian report, suggests that the detection gains are real and that the false-positive burden, while present, has not so far eroded clinical confidence in the tools. Whether that continues to hold as the technology is deployed at lower-volume centres and by less-experienced operators — the trajectory implied by current procurement patterns in South and Southeast Asia — is the next thing the evidence base will need to address. For now, the Indian data point is a useful reminder that when a screening programme adopts a new tool, the most immediate change is not in who survives but in what clinicians see.

Desk note: Monexus treats the Indian pre/post study as a single-site plausibility signal within a longer-running global conversation about clinical AI in endoscopy, rather than as a standalone verdict. The wire frame — “AI doubles adenoma detection” — is accurate on the numbers reported; the more cautious frame asks what proportion of those additional polyps would have mattered, and over what horizon.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/thePrintIndia
• https://t.me/thePrintIndia
• https://t.me/TSN_ua
• https://t.me/TSN_ua
• https://en.wikipedia.org/wiki/Adenoma
• https://en.wikipedia.org/wiki/Colonoscopy
• https://en.wikipedia.org/wiki/Computer-aided_detection
• https://en.wikipedia.org/wiki/Adenoma_detection_rate